Product nameAnti-VEGFA antibody
See all VEGFA primary antibodies
DescriptionRabbit polyclonal to VEGFA
Tested applicationsSuitable for: WB, ELISA, IHC-Pmore details
Species reactivityReacts with: Mouse, Human
Recombinant full length protein corresponding to Mouse VEGFA. Recombinant mouse VEGF164
Database link: Q00731
- SaOS2 cells. Human pancreas tissue.
FormLyophilised:The lyophilized IgG is stable at 4°C for at least one month and for greater than a year when kept at –20°C. When reconstituted in sterile water to a concentration of >0.5 mg/ml the antibody is stable for at least six weeks at 2-4°C.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle.
Storage bufferPreservative: None
Constituents: PBS, pH 7.4
Concentration information loading...
PurityProtein A purified
Our Abpromise guarantee covers the use of ab51745 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||Use a concentration of 0.1 - 1 µg/ml. Predicted molecular weight: 27 kDa. The detection limit for recombinant murine VEGF-A is 1.5-3.0 ng/lane, under either reducing or non-reducing conditions.|
|ELISA||Use a concentration of 1 - 10 µg/ml.|
|IHC-P||Use a concentration of 2 - 10 µg/ml.|
FunctionGrowth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth.
Tissue specificityIsoform VEGF189, isoform VEGF165 and isoform VEGF121 are widely expressed. Isoform VEGF206 and isoform VEGF145 are not widely expressed.
Involvement in diseaseDefects in VEGFA are a cause of susceptibility to microvascular complications of diabetes type 1 (MVCD1) [MIM:603933]. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.
Sequence similaritiesBelongs to the PDGF/VEGF growth factor family.
Cellular localizationSecreted. VEGF121 is acidic and freely secreted. VEGF165 is more basic, has heparin-binding properties and, although a signicant proportion remains cell-associated, most is freely secreted. VEGF189 is very basic, it is cell-associated after secretion and is bound avidly by heparin and the extracellular matrix, although it may be released as a soluble form by heparin, heparinase or plasmin.
- Information by UniProt
- Folliculostellate cell-derived growth factor antibody
- Glioma-derived endothelial cell mitogen antibody
- MGC70609 antibody
Staining of VEGF-A in paraffin-embedded mouse ventricular zone of the CNS (E17) and a perinecrotic area of a human glioblastom.
Top panel: Mouse E17: ventricular zone of the CNS.
Bottom panel: Human glioblastoma: perinecrotic area.
The experiments were performed by Dr. Till Acker and Prof. K.H. Plate, Neurological Institute, Neuropathology, Deutschordenstr. 45, 60528 Frankfurt, Germany
All lanes : Anti-VEGFA antibody (ab51745)
Lane 1 : recombinant mouse VEGF164
Lane 2 : Recombinant human VEGF165
Lane 3 : Recombinant human PlGF-1
Lane 4 : Recombinant rat VEGF-C
Predicted band size: 27 kDa
This product has been referenced in:
- Lu T et al. Blockade of ONECUT2 expression in ovarian cancer inhibited tumor cell proliferation, migration, invasion and angiogenesis. Cancer Sci 109:2221-2234 (2018). Read more (PubMed: 29737581) »
- Lun W et al. MiR-218 regulates epithelial-mesenchymal transition and angiogenesis in colorectal cancer via targeting CTGF. Cancer Cell Int 18:83 (2018). Read more (PubMed: 29977158) »